Canada: Supreme to list shares on TSX Venture Exchange

Supreme Pharmaceuticals has received conditional approval from the TSX Venture Exchange to list the company's common shares on the TSX.V.

John Fowler, President and CEO, stated: "Graduating from the CSE to the TSX.V is an important milestone for Supreme. We enjoyed tremendous success throughout our time on the CSE, which provided us the flexibility we needed in the early stages of our growth. Graduating to the TSX.V prepares us for the next steps in the development of our cannabis business."

Final approval of listing on the TSX.V is subject to Supreme satisfying certain customary conditions required by the TSX.V. Supreme expects that it will be able to satisfy all such conditions by mid-May 2017 and will provide an update once the TSX.V has issued a bulletin confirming the date on which trading on the TSX.V will commence. Following completion of all listing requirements, Supreme's common shares will be voluntarily delisted from the Canadian Securities Exchange and will begin trading on the TSX.V under a new symbol.

For more information:
Supreme Pharmaceuticals
202 – 20 De Boers Dr, Toronto ON
M3J 0H1
Phone: (416) 630-7272
info@supreme.ca
www.supreme.ca